Eden Research Share Discussion Threads

[brucie5] 12/7/2020 12:08

Still a rather big IF around anything this company 'promises'. That is what haunts the share price.

[investingisatrickygame] 11/7/2020 22:46

Super,

Regardless of labs and what others are doing, the potential Corteva deal is there in black and white and the calculation to value is standard. Eden has told us the potential annual value. Therefore, regardless of Chrischas's negativity and opinion, the numbers don't lie.

If Eden sells no Mevalone and no Cedroz (not going to happen) and a commercial deal gets signed with Corteva on those values, Eden will rerate big time. Not long to wait in the big scheme of things for that potential outcome.

[supersonico] 11/7/2020 17:03

But your still here...Why?

[chrischas] 11/7/2020 16:27

If you think a “ a lab” in a nice science park at this stage is going to catch up
On technical know how and nous you are living in cloud cuckoo land .

They are 3 to 4 yrs behind the curve. That 3-yrs :all the competitors have been catching up and can make decisions and trials ,with the equipment they have already got in place With no sales worth anything , no experience of directing future research to generate sales they are absolutely nowhere.
They should be like Novacyt in Southampton : technically competent and dynamic ie able to seize the day.Eden are emphatically not.
I am past believing that they give a toss.

[investingisatrickygame] 10/7/2020 22:13

Chrischas,

Not wishful thinking at all. If Corteva, as RNS'd, comes in, that's where we'll be.

Just do the simple maths, you'll get the same answer

[supersonico] 10/7/2020 20:09

Chrischas
I completely agree that Oskar and Eli have been playing their games for a couple of years here with the explicit aim of keeping the ticket price down for the late arriving happy hour 6p fundraise crew but the Corteva deal and the rapid evolution of the biopesticide market blows your 3-4 year theory imo.

I also believe the IP was delayed because it was in need of some improvement and refinement for partners commercial ambitions which is why Eden had the new terms with UMMS and enhanced the technology as described in the unmentionable YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO-PAYLOADS .

[erinvale] 10/7/2020 19:29

Chrishas - spot on.

[chrischas] 10/7/2020 18:06

Wishful thinking going on here.IT IS the same management they are just 3 to 4 yrs behind where they should be.Nothing as yet has changed it’s just another way to sustain respectability while not having the will or imagination to transform the company sales. Take the money for the next few years and then say oh well did try.

This is a typical British accountant led failure in the making

[investingisatrickygame] 10/7/2020 09:17

Super, I agree.

Another validation of who Eden is today, not the Eden of the past under different management,

Corteva will be all profit and Mevalone will pay for the running of the Company. Cedroz will be profit too.

A successful completion of the Corteva deal this year and re-confirmed annual revenues from that deal of up to/circa €40 million per annum should see Eden's share price trading around a £1, possibly more.

[supersonico] 10/7/2020 07:42

Looks like a good appointment to me.
Corteva ++ is baked in so cash pipeline healthy imo.

Hopefully she will be able to tell us which unmentionable US Patents Sean Smith was referring to with her background and she might even help the Eden team work out which year the kids go back to school and if TT have one product or four ..and if Bayer have 3 or 4 products ready.. oh and lastly she can help look for the moluscicide.

She has plenty to do even before she puts her lab coat on..she'll have fun telling Akala to take his cosseted Tomas Alfredson Swiss Noise rock Blu-ray collection that he has been accumulating over the last two years.. out of the centrifuge.

[erinvale] 10/7/2020 07:06

RNS: Eden appoints head of biology and dev. More process. The company urgently needs to sell stuff, in credible quantity. What it does not need are new premises, new consultants, new notepaper, new office chairs. This is a risible continuation of Eden’s idea that saying you’ll do something (eg get sales) is tantamount to doing it. Shareholders have been promised tangible progress for years - it is never delivered. This company is a farcical disaster.

[supersonico] 09/7/2020 12:58

Speculator59.
I'm surprised the elsewhere folk have the time to discuss this or do they have too much time on their hands? ;)

Investing,
Remember your watching the top of the Edenberg. I'm confident that there is a considerable amount of activity below the water line and the Corteva deal is just one of those submerged deals yet to be confirmed. A rice/wheat/blast announcement is on the cards inthecoming imo.

[speculator59] 09/7/2020 11:48

I was speculating on the cost of this and simply said elsewhere - sounds expensive.

However, as someone who rejoiced in the title of - Laboratory Manager - earlier in my life, I can tell you that that was a small part of my job alongside being an operational scientist for a group of 50 works.

I suspect that, here, it will be a research scientist who manages the lab on the side and has one or two junior lab techs/scientists to work with him/her.

In reality, such staff are not well paid generally.

We shall wait and see.

[investingisatrickygame] 09/7/2020 11:47

Although the share price is steady, I'm surprised we are not sitting higher after the fund raise, the Corteva RNS and the lab RNS which does signal intent and affordability.

Our current share price makes no sense to me. The sooner we can (hopefully) get confirmation of a commercial deal with Corteva, the better. If the market doesn't materially re-rate Eden's value at that point in time, I don't know what will.

[supersonico] 09/7/2020 11:39

No Idea but I imagine they will need a Lab manager for starters if they are doing the bring it in da house thang.

[investingisatrickygame] 09/7/2020 11:27

"Still only 10 employees @ Eden so who's running the Lab?"

Who do you think is running the lab?

[supersonico] 09/7/2020 11:20

Still only 10 employees @ Eden so who's running the Lab?

[supersonico] 09/7/2020 08:28

Wheat & Rice Blast

Barbara Valent, Kansas State University


Nick Talbot, University of Exeter


Sophien Kamoun, The Sainsbury Laboratory

[supersonico] 08/7/2020 09:04

BASF Rice Blast Market news.

SELTIMA RESPECTS LMR
Remains under control in the crop with the new BASF product against the brusone

Seltima, New® BASF fights the Brusone and limits the residue on the grain, allowing the farmer to sell the crop without problems. A study by the Department of Agricultural, Forestry and Food Sciences (DISAFA) at the University of Turin analysed the new flagship product of German society in terms of residues: "With two fungic acid treatments against Brusone, spaced 10 days apart, the residues measured in both the rice and the unbraded rice are found to be inferior to LMR," explains the final note. As already observed in 2018, also in 2019 in single treatment with Seltima, New® at the BBCH 47-51 stage there was no residue of F500® neither in the rice nor in the unbraded rice.' The residues in the rice paddy and soil submerged water are also greatly reduced as a result of the encapsulation of the active ingredient. DISAFA studied the residuality in the plant and grain and the rice paddy dissipation dynamics of the fungicide F500® (Pyraclostrobin) to see if the special capsule formulation of Seltima® would have an advantage over a more traditional formulation of F500®, as an emulsifying concentrate, in concentrated suspension formulation, used in rice paddling against Pyricular Oricular.

A green soul
The study was carried out at a rice farm in Zeme (Pavia) on medium-sized land. The use of the Formula Seltima® has allowed the maximum limit of residue in the grain to be fully respected in the case of double application and residues below the quantification limit even on risone when applied only once before the start of the spiking. Three days after treatment, the application with Seltima® resulted in the presence of the molecule F500® free in the submerged waters 90% lower than the formulation in emulsifier concentrate without determining a greater presence in the soil. Seltima, New® it is highly innovative because of the encapsulation of the active ingredient, which allows to reconcile the fight against the brusone – indispensable for the company rice – to environmental sustainability. The encapsulation of the active substance F500® (Pyraclostrobin) allows controlled release directly on the surface of the leaf. Claudio Pivi, Crop & Wallet Manager at BASF explains: "Once the leaves are reached, the capsules, as soon as the drying process begins, open by releasing the active substance. This allows for rapid but continuous penetration into the plant, which guarantees excellent protection from the attack of the burn and the ability to maintain an interval between applications for up to 21 days. In water, however, the capsules remain intact, preventing the release of the active substance; In addition, intact capsules tend to plummet into the soil, reducing the exposure of aquatic organisms to the active substance. The capsules that reach the soil progressively release the active substance, which is rapidly degraded mainly by microbial activity, light exposure and anaerobic conditions.' A green soul that results in a lower presence in the risone.



From post 7722
27 März 2017
Dow, BASF, Eastman stir up new formulas for safer chemicals
Consumer marketplace seems to be the most powerful force inspiring chemical and materials manufacturers to create safer chemicals.


Parked

[supersonico] 07/7/2020 08:29

Indeed Chrischas but imagine how much more valuable the unmentionable IP is when your based on a science park.

[chrischas] 07/7/2020 07:26

In the same building is a company supplying science boxes for schools...…
it would make a nice present for the BOD

[supersonico] 06/7/2020 22:19

Letting the right Rats in since May 2018

[chrischas] 06/7/2020 16:17

All they need to do now is get some rats for the lab.
Must have caught plenty when they left the old place.

At least they wont need a lab cleaner on the pay roll this year.

[supersonico] 04/7/2020 08:41

Investing, re your 7867 of 7875 post.

As you know I'm a strong believer in Bayer being a big part of Eden's future beyond CAP as they have been part of the in the coming short order parallel delay story now for over 7years.

The question for me is around how they work with the IP. This Bayer patent using terpenes / essential oils specifically excludes some of Eden's SustainE core ingredients which to me invites the question of why specifically exclude these oils? and how is Bayer going to use the volatile oils listed in it's products? and obviously another question is are they developing this with SustainE in mind.

A load of questions for those who follow the story but have no understanding of the chemistry so likely barking mad up the wrong tree.

METHODS OF INHIBITING, PREVENTING, KILLING AND/OR REPELLING INSECTS USING SIMULATED BLENDS OF CHENOPODIUM EXTRACTS

The present invention provides a spray formulation comprising as a single active ingredient a simulated combination of a Chenopodiumambrosioides essential oil extract similar to ambrosioid, wherein the simulated combination consists essentially of substantially pure α-terpinene, p-cymene and limonene, in which substantially pure means that each of α-terpinene, p-cymene and limonene contains less than or equal to 10% of other compounds, where each of substantially pure α-terpinene, p-cymene and limonene is not obtained from of a Chenopodium extract. The present invention provides compositions that comprise three terpenes, i.e. α-terpinene, p-cymene and limonene, as pesticide-active chemical compounds. The three terpenes in the compositions used in the present invention can be obtained, for example, from an extract of a genus / plant species other than Chenopodium 7 ambrosioides similar to ambrosioid, which produces such terpenes, or synthetically produced (that is, by a chemical synthesis process) , and / or as a compound naturally produced by any organism (that is, as a compound separated from an extract by itself).

In one embodiment, all three terpenes are from natural analogues of such terpenes as an extract from other plant species or other organisms. In yet another embodiment, all three terpenes are synthetic versions of Chenopodiumambrosioid terpenes obtainable similar to ambrosioides or other plant species or other organisms. In yet other embodiments, the three terpenes are any possible combination of natural and / or synthetic versions of the three terpenes. In another embodiment, the three terpenes are obtained from any source or by any means except a Chenopodiumambrosioidesou extract except a Chenopodium extract.

In one embodiment, the compositions comprise an excipient and a simulated combination consisting essentially of substantially pure α-terpinene, p-cymene and limonene not obtained from Chenopodium ambrosioides or not obtained from Chenopodium, where substantially pure means that each of α-terpinene, p-cymene and limonene contains less than or equal to 10% of other compounds. In another embodiment, the compositions consist essentially of an excipient and a simulated combination consisting essentially of substantially pure α-terpinene, p-cymene and limonene, where substantially pure means that each of entreα-terpinene, p-cymene and lemon contains less than or equal to 10% of other compounds.

In some embodiments, the compositions do not contain thymol, carvacol, carvone, carveol and / or nerol. In particular embodiments, the simulated combinations 8 in the above compositions are not a Chenopodium ambrosioides extract or a Chenopodium extract.

In another embodiment, the pesticide-active compositions of the present invention only include a synthetic combination that simulates the essential oil extract of or based on those found in Chenopodiumambrosioid-like ambrosioides. In still other embodiments, the compositions used in the methods of the present invention are reconstituted, as further explained here. In some embodiments, the simulated combinations comprise the three substantially pure α-terpinene, p-cymene and limonene, with at least one volume filler that replaces the volume occupied by the smaller components normally present in Chenopodium ambrosioid-like ambrosioid extract. In some embodiments, the volume filler is vegetable oil or mineral oil. In other embodiments, the simulated combinations essentially consist of α-terpinene, p-cymene and limonene, and an oil in which α-terpinene, p-cymene and limonene are substantially pure and are not obtained from an extract of Chenopodium, and the excipient is not an essential oil.